Pages

Thursday, August 23, 2007

News Update: August 2007

I’m going to take a break from blogging until after Labor Day. In the meantime, here are a few stories that you may have missed this month. Don't worry -- I’ll be back in September!

1) Pharmacy fights backThe Average Manufacturer Price (AMP) war has now moved to Congress, where multiple bills benefiting retail pharmacy have been introduced. Here are the major bills and their key provisions, which I’ll discuss further in upcoming posts:

3) Cracking the Top 100Drug Channels is now #69 on the Healthcare 100 list of top blogs on health and medicine. (There are actually 390 blogs on the list, so it's a good page to bookmark.) Thanks for helping to make Drug Channels such a success!

I also want to give a special shout-out to Al Godley of Edge Dynamics, who was named to the PharmaVOICE 100 list of industry influencers. Congratulations on this well-deserved recognition, Al!

4) Phun Phact about PhillyYour friendly neighborhood pharmacy supply chain blogger is proud to live in the second "bloggiest" city in the US. Who knew?

DISCLAIMERThe analyses on this website are based on information and data that are in the public domain. Any conclusions, findings, opinions, or recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., Drug Channels Institute, and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations, on this website or otherwise. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

The comments contained on this site come from members of the public and do not necessarily reflect the views of Drug Channels Institute or the author. Neither Drug Channels Institute nor the author endorse or approve of their content. Drug Channels Institute and the author reserve the right to remove or block comments, but are under no obligation to explain individual moderation decisions.

The public domain use of our materials includes linking to our website. You do not need to obtain special permission to link to the Drug Channels site. The material on this site is protected by copyright law. Unauthorized reproduction or distribution of this material may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. We do not intend to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws. We do not permit our articles to be republished without prior written permission.

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels Institute, or any of its employees.